1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Stored deadline is 2026-06-30. Page shows three active RFPs: HIV Prevention LOI due Jan 30, HIV RESONATE LOI due May 4, and Panviral GATHER AND LISTEN LOI due July 12, 2026. Rolling submissions also accepted for other virology topics.
"RFP Topics of Interest - Virology" is currently closed and not accepting applications.
RFP Topics of Interest - Virology is sponsored by Gilead Sciences. Gilead Sciences offers Requests for Proposals (RFPs) and Topics of Interest in Virology, including areas related to HIV, viral hepatitis, and neglected & emerging viruses and pandemic preparedness.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Gilead Sciences: Virology RFP Opportunities Research Funding Programs External-Sponsored Research Virology RFP Opportunities Virology & Infectious Diseases RFP Opportunities Some content on this site is not intended for people outside of the United States. Virology & Infectious Diseases RFP Programs We offer both Request for Proposal (RFP) Programs and RFP Topics of Interest.
An RFP Program specifically describes the research topic and may include detailed instructions on submitting a Letter of Interest (LOI) and full proposal. RFP Topics of Interest are brief descriptions of research topics that are of interest to the company. Both RFP types can be submitted through Gilead’s online proposal submission portal, Gilead OPTICS.
For RFP Programs focused on community organizations, visit Community-Based Participatory Research .
HIV Prevention - INCLUSION Global 2026 Implementation research of twice-yearly Lenacapavir to address unmet needs in HIV prevention HIV: RESONATE 2026, BIC/LEN Research to support clinical & community decisions and medical management of HIV Panviral: GATHER AND LISTEN 2026 Research to advance integrated HIV and viral hepatitis care and address gender and structural barriers to improve equitable access, engagement, and outcomes across diverse populations Gilead will evaluate all Letters of Interest (LOIs) received in Gilead OPTICS by June 30, 2026.
LOIs should address one or more of the following topic areas: Safety and efficacy of AmBisome (liposomal amphotericin B*) alone or in combination with other antifungals AmBisome in patients with hematologic malignancies or disease AmBisome in critically ill patients in the intensive care unit (ICU) Characteristics of patients with breakthrough invasive fungal infections after antifungal prophylaxis and role of AmBisome as salvage treatment Nebulized AmBisome therapy – increased understanding of optimal dosing schedules** Intermittent AmBisome dosing strategies** AmBisome in empirical (early) treatment Epidemiology of invasive fungal disease The role of AmBisome in light of changing epidemiology due to environmental changes and evolving resistance profiles – multi-country evaluation *Researchers should consider the local label or indication as well as the availability of liposomal amphotericin B and contact their local Gilead medical representative for any questions.
**The use of AmBisome in this form or dosing schedule remains investigational, and its safety and efficacy have not been established by any regulatory authority. Gilead will evaluate all Concepts addressing the following topics of interest (TOI) on a rolling basis until funds are exhausted.
* Research Topic: Implementation of updated HBV treatment guidelines and shared-decision making (SDM) and its impact on HBV treatment initiation and/or clinical outcomes. In what ways can SDM address patient, provider, and system-level barriers to HBV care under the updated HBV treatment guideline recommendations, and what patient-centered criteria are essential for effective HBV SDM tools?
How should SDM be operationalized and sustainably integrated into HBV care, and what impact does its implementation have on HBV treatment initiation, adherence, and disease control? *Concepts only proposing new implementation of HBV testing alone will not be considered. Gilead will evaluate all concepts received on a rolling basis until funds are exhausted.
This TOI program is open to all geographies.
The program will consider concepts which focus on the topics below: Linkage to care and treatment of HCV+ pregnant patients through multi-specialty coordination: Studies which implement models of care supporting informed treatment initiation for HCV+ pregnant patients, including post-treatment follow up and post-partum outcomes Implementation and optimization of HDV testing and linkage to care strategies to improve identification of HDV infection and timely connection to appropriate specialty care in the United States.
To evaluate feasibility, adoption, reach, and linkage-to-care outcomes of reflex or double-reflex HDV testing among HBsAg-positive populations across healthcare systems, with a focus on community clinics, Federally Qualified Health Centers (FQHCs) and safety-net hospitals.
To characterize variations in the HDV care cascade across community clinics, FQHCs and safety-net hospitals, geographies, and patient sub‑populations defined by social determinants of health and higher HDV burden, and identify, implement, and evaluate best‑practice or evidence‑based strategies to address critical linkage‑to‑care drop‑offs.
Apply for Research Funding Together, we can generate critical, high-quality research that has an impact on clinical decision-making and patients’ lives.
According to the current listing, eligibility includes: Researchers and organizations aligned with Gilead's therapeutic areas in virology; rolling submissions evaluated via Gilead OPTICS portal. Confirm the full requirements in the official notice before applying.
The published deadline was July 12, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
RFP Topics of Interest - Virology is funded by Gilead Sciences. Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
The U.S. Government Policy for Stopping High-Risk Life Sciences Research, released July 28, 2026 under EO 14292 and implemented at NIH through NOT-OD-26-101, replaces mitigation with prohibition. It bans dangerous gain-of-function research outright, gates potential DGOF behind government-wide review, and creates International Research of Concern — a research-security regime wearing biosafety clothing. Penalties run to five-year debarment and False Claims Act exposure.
Read articleSchmidt Sciences opened a 'Scaling AI Safety for a Multi-Agent World' program with awards up to $1 million and an August 8, 2026 deadline. Against a backdrop of federal research slowdowns, here is why private science philanthropy matters more than ever, how these funders differ from federal agencies, and how researchers should approach them.
Read articleNSF's Arctic Research Opportunities solicitation funds roughly 75 awards a year — up to $50 million — across six program areas from natural sciences to social sciences to the Arctic Observing Network. The July 15, 2026 target date is not a hard deadline, and understanding that distinction is the first strategic decision an Arctic researcher makes. Here is how the six doors differ and how to choose the right one.
Read article